2012
Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation
Jenq R, Ubeda C, Taur Y, Menezes C, Khanin R, Dudakov J, Liu C, West M, Singer N, Equinda M, Gobourne A, Lipuma L, Young L, Smith O, Ghosh A, Hanash A, Goldberg J, Aoyama K, Blazar B, Pamer E, van den Brink M. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. Journal Of Experimental Medicine 2012, 209: 903-911. PMID: 22547653, PMCID: PMC3348096, DOI: 10.1084/jem.20112408.Peer-Reviewed Original ResearchConceptsAllogeneic bone marrow transplantationBone marrow transplantationIntestinal inflammationMarrow transplantationAllogeneic BMT recipientsPotential risk factorsSubsequent GVHDHost diseaseBMT recipientsRisk factorsGVHDMouse modelResident gut microbesInflammationIntestinal microbiotaSignificant protectionGut floraHuman recipientsHuman floraInitial onsetGut microbesLongitudinal studyTransplantationMicrobiotaMice
2005
A Role for CD54 (Intercellular Adhesion Molecule-1) in Leukocyte Recruitment to the Lung During the Development of Experimental Idiopathic Pneumonia Syndrome
Gerbitz A, Ewing P, Olkiewicz K, Willmarth N, Williams D, Hildebrandt G, Wilke A, Liu C, Eissner G, Andreesen R, Holler E, Guo R, Ward P, Cooke K. A Role for CD54 (Intercellular Adhesion Molecule-1) in Leukocyte Recruitment to the Lung During the Development of Experimental Idiopathic Pneumonia Syndrome. Transplantation 2005, 79: 536-542. PMID: 15753842, DOI: 10.1097/01.tp.0000151763.16800.b0.Peer-Reviewed Original ResearchConceptsDevelopment of IPSIdiopathic pneumonia syndromeGVHD target organsBone marrow transplantationMonoclonal blocking antibodyPulmonary vascular expressionICAM-1Pneumonia syndromeLeukocyte recruitmentBlocking antibodiesVascular expressionTarget organsBronchoalveolar lavage fluid levelsExperimental Idiopathic Pneumonia SyndromeMinor histocompatibility antigenic differencesAllogeneic bone marrow transplantationEndothelial cellsAllogeneic BMT recipientsMurine BMT systemLavage fluid levelsAdhesion molecules CD54ICAM-1 deficiencyICAM-1 expressionWild-type recipientsWild-type controls
2003
Repifermin (keratinocyte growth factor-2) reduces the severity of graft-versus-host disease while preserving a graft-versus-leukemia effect
Clouthier S, Cooke K, Teshima T, Lowler K, Liu C, Connolly K, Ferrara J. Repifermin (keratinocyte growth factor-2) reduces the severity of graft-versus-host disease while preserving a graft-versus-leukemia effect. Transplantation And Cellular Therapy 2003, 9: 592-603. PMID: 14506661, DOI: 10.1016/s1083-8791(03)00230-1.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBone Marrow TransplantationCD4 Lymphocyte CountCD8-Positive T-LymphocytesCell DivisionCell Line, TumorDisease Models, AnimalFemaleFibroblast Growth Factor 10Fibroblast Growth FactorsGraft vs Host DiseaseGraft vs Leukemia EffectHumansInterferon-gammaInterleukin-2IntestinesLipopolysaccharidesLiverLymphocyte CountMiceMice, Inbred C57BLMice, Inbred StrainsRecombinant ProteinsSpleenT-LymphocytesT-Lymphocytes, CytotoxicTransplantation, HomologousTumor Necrosis Factor-alphaConceptsBone marrow transplantationAllogeneic bone marrow transplantationAllogeneic BMT recipientsSystemic GVHDGVL effectHost diseaseBMT recipientsTumor necrosis factor alphaBeneficial GVL effectInduction of GVHDSeverity of graftToxicity of GVHDMurine BMT modelBone marrow inoculumNecrosis factor alphaT cell proliferationRecombinant human keratinocyte growth factorHuman keratinocyte growth factorKeratinocyte growth factorLeukemia effectLeukemia responseSerum levelsMarrow transplantationControl miceOrgan histopathology